The University of Iowa


Designing Clinical Trials for Dystonia

Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JLP, Yeatts SD, and Jinnah HA
Neurotherapeutics. 2014 January; 11 (1) 117-127.

Association of Cerebrospinal Fluid Aβ1-42, t-tau, p-tau181, and α-synuclein Levels with Clinical Features of Early Drug Naïve Parkinson’s Disease Patients

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligorska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM and the Parkinson’s Progression Marker Initiative Investigators
Archives of Neurology. 2013 October; 70 (10) 1277-1287.

Clinical Features and Racial/Ethnic Differences among the 3020 Participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) Trial

White CL, Szychowski JM, Roldan A, Benavente MF, Pretell EJ, Del Brutto OH, Kase CS, Arauz A, Meyer BC, Meissner I, Demaerschalk BM, McClure LA, Coffey CS, Pearce LA, Conwit R, Irby LH, Peri K, Pergola PE, Hart RG, and Benavente OR for the SPS3 Investigators
Journal of Stroke and Cerebrovascular Diseases. 2013 August; 22 (6) 764-774.